• Je něco špatně v tomto záznamu ?

Azilsartan improves glycemic status and reduces kidney damage in zucker diabetic fatty rats

MA. Hye Khan, J. Neckář, J. Haines, JD. Imig,

. 2014 ; 27 (8) : 1087-95.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc15023548
E-zdroje Online Plný text

NLK ProQuest Central od 2000-01-01 do 2015-12-31
Health & Medicine (ProQuest) od 2000-01-01 do 2015-12-31

Odkazy

PubMed 24598210
DOI 10.1093/ajh/hpu016
Knihovny.cz E-zdroje

BACKGROUND: Azilsartan medoxomil (AZL-M), an angiotensin II receptor blocker, demonstrates antihypertensive and organ protective effects in hypertension. We investigated the efficacy of AZL-M to ameliorate metabolic syndrome and kidney damage associated with type 2 diabetes using Zucker diabetic fatty (ZDF) rats. METHODS: ZDF rats were treated with vehicle or AZL-M for 8 weeks. Zucker diabetic lean (ZDL) rats were used as controls. Urine and plasma samples were collected for biochemical analysis, and kidney tissues were used for histopathological and immunohistopathological examination at the end of the 8-week protocol. RESULTS: ZDF rats were diabetic with hyperglycemia and impaired glucose tolerance, and AZL-M ameliorated the diabetic phenotype. ZDF rats were hypertensive compared with ZDL rats (181±6 vs. 129±7mm Hg), and AZL-M decreased blood pressure in ZDF rats (116±7mm Hg). In ZDF rats, there was marked renal damage with elevated proteinuria, albuminuria, nephrinuria, 2-4-fold higher tubular cast formation, and glomerular injury compared with ZDL rats. AZL-M treatment reduced renal damage in ZDF rats. ZDF rats demonstrated renal inflammation and oxidative stress with elevated urinary monocyte chemoattractant protein 1 excretion, renal infiltration of macrophages, and elevated kidney malondialdehyde levels. AZL-M reduced oxidative stress and inflammation in ZDF rats. CONCLUSIONS: Overall, we demonstrate that AZL-M attenuates kidney damage in type 2 diabetes. We further demonstrate that anti-inflammatory and antioxidative activities of AZL-M contribute to its kidney protective action.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15023548
003      
CZ-PrNML
005      
20150722125234.0
007      
ta
008      
150709s2014 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1093/ajh/hpu016 $2 doi
035    __
$a (PubMed)24598210
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Hye Khan, Md Abdul $u Department of Pharmacology & Toxicology, Medical College of Wisconsin, Milwaukee, Wisconsin;
245    10
$a Azilsartan improves glycemic status and reduces kidney damage in zucker diabetic fatty rats / $c MA. Hye Khan, J. Neckář, J. Haines, JD. Imig,
520    9_
$a BACKGROUND: Azilsartan medoxomil (AZL-M), an angiotensin II receptor blocker, demonstrates antihypertensive and organ protective effects in hypertension. We investigated the efficacy of AZL-M to ameliorate metabolic syndrome and kidney damage associated with type 2 diabetes using Zucker diabetic fatty (ZDF) rats. METHODS: ZDF rats were treated with vehicle or AZL-M for 8 weeks. Zucker diabetic lean (ZDL) rats were used as controls. Urine and plasma samples were collected for biochemical analysis, and kidney tissues were used for histopathological and immunohistopathological examination at the end of the 8-week protocol. RESULTS: ZDF rats were diabetic with hyperglycemia and impaired glucose tolerance, and AZL-M ameliorated the diabetic phenotype. ZDF rats were hypertensive compared with ZDL rats (181±6 vs. 129±7mm Hg), and AZL-M decreased blood pressure in ZDF rats (116±7mm Hg). In ZDF rats, there was marked renal damage with elevated proteinuria, albuminuria, nephrinuria, 2-4-fold higher tubular cast formation, and glomerular injury compared with ZDL rats. AZL-M treatment reduced renal damage in ZDF rats. ZDF rats demonstrated renal inflammation and oxidative stress with elevated urinary monocyte chemoattractant protein 1 excretion, renal infiltration of macrophages, and elevated kidney malondialdehyde levels. AZL-M reduced oxidative stress and inflammation in ZDF rats. CONCLUSIONS: Overall, we demonstrate that AZL-M attenuates kidney damage in type 2 diabetes. We further demonstrate that anti-inflammatory and antioxidative activities of AZL-M contribute to its kidney protective action.
650    _2
$a blokátory receptoru 1 pro angiotenzin II $x terapeutické užití $7 D047228
650    _2
$a zvířata $7 D000818
650    _2
$a benzimidazoly $x terapeutické užití $7 D001562
650    _2
$a krevní glukóza $x metabolismus $7 D001786
650    _2
$a krevní tlak $x účinky léků $7 D001794
650    _2
$a diabetické nefropatie $x patologie $x prevence a kontrola $7 D003928
650    _2
$a cévní endotel $x účinky léků $7 D004730
650    _2
$a porucha glukózové tolerance $x prevence a kontrola $7 D018149
650    _2
$a glukózový toleranční test $7 D005951
650    _2
$a hyperglykemie $x farmakoterapie $7 D006943
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a oxadiazoly $x terapeutické užití $7 D010069
650    _2
$a oxidační stres $x účinky léků $7 D018384
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Zucker $7 D011924
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Neckář, Jan $u Department of Pharmacology & Toxicology, Medical College of Wisconsin, Milwaukee, Wisconsin; Institute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic;
700    1_
$a Haines, Jasmine $u Department of Pharmacology & Toxicology, Medical College of Wisconsin, Milwaukee, Wisconsin;
700    1_
$a Imig, John D $u Department of Pharmacology & Toxicology, Medical College of Wisconsin, Milwaukee, Wisconsin; Cardiovascular Center, Medical College of Wisconsin, Milwaukee, Wisconsin. jdimig@mcw.edu.
773    0_
$w MED00000255 $t American journal of hypertension $x 1941-7225 $g Roč. 27, č. 8 (2014), s. 1087-95
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24598210 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150709 $b ABA008
991    __
$a 20150722125312 $b ABA008
999    __
$a ok $b bmc $g 1083885 $s 906541
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 27 $c 8 $d 1087-95 $i 1941-7225 $m American journal of hypertension $n Am J Hypertens $x MED00000255
LZP    __
$a Pubmed-20150709

Najít záznam

Citační ukazatele

    Možnosti archivace